Verimatrix Virtual Summit to Offer the Industry’s Latest Insights into Secure Video Delivery and Mobile Application Protection July 8-9
30.6.2020 18:45:00 EEST | Business Wire | Press release
Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced its second virtual event this year designed to showcase how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces. The Verimatrix Summer Summit consists of webcasts and private meetings taking place Wednesday, July 8, and Thursday, July 9, 2020.
“Now more than ever, organizations need to provide their customers with compelling experiences – but those experiences must be protected,” said Asaf Ashkenazi, COO of Verimatrix. “The Verimatrix Summer Summit will showcase why security matters more than ever -- and why in today’s modern connected world, security should be intuitive, user-friendly, and fast."
To kick off the Summit, Verimatrix Chairman and CEO Amedeo D’Angelo will underscore the importance of reliable and trustworthy security in the high-growth areas of video content, mobile applications and connected devices.
Verimatrix Virtual Summit Experience
Trusted Security: What it Means to Be a Trusted Security Partner
Wednesday, July 8, 6:30am PT / 1:30pm GMT
Amedeo D’Angelo, Chairman and CEO of Verimatrix, will explore what it means to be a trusted security partner, how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces, and why the future of scalable, cost-effective SaaS security in the cloud is so exciting.
Every Second Counts: Building Better Sports Fan Experiences Through Secure Mobile Apps and Connected Game Play
Wednesday, July 8, 7:00am PT / 2:00pm GMT
Produced and moderated by SportsPro, this webinar will showcase how today’s technological change is forever altering fan perceptions and demands for the sporting experience. Franchises who provide trusted gameday ecosystems will win over the hearts, minds and pocketbooks of fans – while preserving valuable revenue streams. Panelists include Leanne Johnson, VP of Digital for the Milwaukee Bucks and Lucas von Cranach, CEO and Founder of Onefootball. Eoin Connolly, Editor-At-Large for SportsPro, will moderate.
Cloud Speed Ahead: Unlocking New Opportunities with Secure Content Distribution
Wednesday, July 8, 8:00am PT / 3:00pm GMT
Produced by Omdia, this webinar will explore how content providers are efficiently setting up new distribution channels around the world by maximizing novel OTT direct-to-consumer strategies without breaking the bank. Allen Tatara, Sr. Manager, Webinar Events at Omdia will moderate. Panelists will include Geoff Stedman, Enterprise Media Strategist at AWS Elemental, Asaf Askenazi, Chief Operating Officer at Verimatrix and Merrick Kingston, Associate Director at Omdia.
Apps Under Siege: Understanding Today’s Threats to Web/Mobile Applications and How to Defend Your IP While Safeguarding Customers
Wednesday, July 8, 11:30am PT / 6:30pm GMT
Experts from Jscrambler and Verimatrix will discuss how the lack of application protection is a giant blind spot and source of risk for many companies. Whether they want to acknowledge it or not, virtually every company today is in the app business. This webinar will reveal how to protect apps from harm without degrading the user experience. Lu Bolden, Chief Revenue Officer at Verimatrix will moderate. Panelist will include Pedro Fortuna, Co-Founder & CTO at Jscrambler and Neal Michie, Director Product Management at Verimatrix.
Defend and Protect: How Cybercriminals Are Hacking Healthcare Workflows & How to Stop Them
Thursday, July 9, 8:00am PT / 3:00pm GMT
Moderated by Adam Turinas, this panel session will explore how cybercriminals can cripple healthcare workflows. It will uncover how tele-health platforms, apps and devices can be hacked relatively easily, share examples of breaches and review the latest security techniques. The results of a security effectiveness test of the world’s top 20 healthcare apps will be shared during the session. The webinar will be moderated by Adam Turinas, CEO & Founder of HealthLaunchpad. Panelists include John Ulett, CIO of CentraState Healthcare System, John Hendricks, CTO of Huntzinger Management Group, Brian Lawrence, Director Solution Engineering at NowSecure and Asaf Ashkenazi, Chief Operating Officer at Verimatrix.
Churning It Around: How to Identify and Retain At-Risk Video and Internet Service Subscribers Using Data Stories
Thursday, July 9, 9:00am PT / 4:00pm GMT
This panel will explore how security vendors and systems integrators are working with operators to utilize the latest data harvesting & analytics tools to surface subscriber profitability stories. This can lead to actionable insights powerful enough to boost consumption rates, reduce churn and increase ARPU – all of which are especially critical in a climate of tight pocketbooks caused by COVID-19. Moderated by Sebastian Braun, Director Product Management at Verimatrix, this panel will feature Luc Bleylevens, Senior Product Director, Subscriber Retention Management at Cleeng, Daragh O Brien, CEO & Managing Director of Castlebridge and Derek Harrar, CEO of Zodiac.
Adapt or Die: The Content Distribution Business Model in Flux
Thursday, July 9, 11:30am PT / 6:30pm GMT
Speakers from Xperi (TiVo) and 3Vision come together for this insightful session on the impact of COVID-19 on the traditional Hollywood business and their audiences. Topics to be explored include what’s changing within the content distribution business model and why, the shifting power of content producers, trends in security technologies and integration methods and more. Moderated by Lu Bolden, Chief Revenue Officer at Verimatrix, this webinar will feature Nic Wilson, Head of Customer Success at TiVo and Jack Davison, EVP of 3Vision.
To learn more about the Verimatrix Summer Summit, or register to attend any of the sessions go to www.summit.verimatrix.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005500/en/
Contact information
Investor and media
Investor Relations
Richard Vacher Detournière
General Manager & Chief Financial Officer
+33 (0)4 42 905 905
finance@verimatrix.com
Contact Media
Kelly Foster
+1 619 224 1261
kfoster@verimatrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
